Correlation Between Hyperhomocysteinemia and Outcomes of Patients With Acute Myocardial InfarctionMa, Yi MD; Li, Li BSc; Geng, Xue-Bin MSc; Hong, Ye BSc; Shang, Xiao-Ming MD; Tan, Zheng MD; Song, Yu-Xin BSc; Zhao, Guo-Yu MSc; Zhao, Bi-Qiong BSc; Tian, Mei-Rong MScAmerican Journal of Therapeutics: November/December 2016 - Volume 23 - Issue 6 - p e1464–e1468 doi: 10.1097/MJT.0000000000000130 Original Articles Abstract Author Information Overwhelming clinical and epidemiological studies have identified elevated plasma total homocysteine (Hcy) as new important risk factor for atherosclerotic vascular disease. But the relationship between outcome and hyperhomocysteinemia in patients with acute myocardial infarction (AMI) has been rarely reported. This study aimed to evaluate the association between hyperhomocysteinemia and short-term outcomes of patients with AMI. Eight hundred five patients were divided into high Hcy level group (group H: N = 457) and low Hcy level group (group L: N = 348) according to the plasma Hcy levels of 15 mmol/L. The comparisons were made between 2 groups in the following aspects: sex, hypertension, diabetes, hyperlipidemia, the time for symptom from onset to percutaneous coronary intervention, homoccyteine, creatine phosphokinase isoenzyme (creatine kinase myocardial band), and the incidence of 30-day adverse events. The incidences of heart failure, cardiac rupture, death, and the total adverse cardiovascular events were statistically significantly higher in group H than in group L. But the incidence of postoperative angina pectoris and reinfarction was similar between groups. The results of logistic regression showed that the incidence of 30-day adverse events was closely related to the age and the level of Hcy. An elevated plasma total Hcy level in patients with AMI experienced pemutaneous coronary intervention may be related to the short-term outcomes. An elevated high plasma Hcy level also seems to be an independent predictor of 30-day cardiovascular events in patients with AMI. Department of Cardiovascular Medicine, The Tangshan Affiliated Clinical Hospital of Hebei Medical University, Tangshan, China. Address for correspondence: Department of Cardiovascular Medicine, The Tangshan Affiliated Clinical Hospital of Hebei Medical University, Tangshan, Hebei 063000, China. E-mail: firstname.lastname@example.org The authors have no conflicts of interest to declare. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.